BSC-0826

Sunshine Biopharma's Canadian subsidiary, Nora Pharma Inc., has introduced generic Lurasidone for schizophrenia and bipolar depression treatment, entering the global $1.2 billion market that is projected to reach $2.5 billion by 2033.

Sunshine Biopharma's Canadian subsidiary, Nora Pharma Inc., has introduced generic Everolimus to the Canadian market, targeting multiple cancer indications including advanced renal cell carcinoma and breast cancer.

Sunshine Biopharma's K1.1 mRNA Lipid Nanoparticle therapy demonstrated significant anti-tumor activity against hepatocellular carcinoma in preclinical studies, reducing tumor growth with good tolerability.

Sunshine Biopharma's Canadian subsidiary, Nora Pharma Inc., has acquired rights to two gastrointestinal drugs, with Prucalopride already launched and a second product planned within 9 months.

The FDA has approved Fylnetra (pegfilgrastim-pbbk), a biosimilar referencing Neulasta, developed by Amneal Pharmaceuticals and Kashiv Biosciences.